NZ702967A - Diclofenac formulations - Google Patents
Diclofenac formulationsInfo
- Publication number
- NZ702967A NZ702967A NZ702967A NZ70296713A NZ702967A NZ 702967 A NZ702967 A NZ 702967A NZ 702967 A NZ702967 A NZ 702967A NZ 70296713 A NZ70296713 A NZ 70296713A NZ 702967 A NZ702967 A NZ 702967A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diclofenac
- gel formulations
- provides improved
- treatment
- diclofenac formulations
- Prior art date
Links
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title abstract 6
- 229960001259 diclofenac Drugs 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176115 | 2012-07-12 | ||
| PCT/EP2013/064123 WO2014009241A1 (en) | 2012-07-12 | 2013-07-04 | Diclofenac formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702967A true NZ702967A (en) | 2017-07-28 |
Family
ID=48741196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702967A NZ702967A (en) | 2012-07-12 | 2013-07-04 | Diclofenac formulations |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9999590B2 (enExample) |
| EP (2) | EP3275466A1 (enExample) |
| JP (2) | JP6259454B2 (enExample) |
| KR (1) | KR20150030752A (enExample) |
| CN (1) | CN104428003B (enExample) |
| AU (1) | AU2013289403B2 (enExample) |
| BR (1) | BR112015000329A2 (enExample) |
| CA (1) | CA2878784A1 (enExample) |
| HK (1) | HK1204973A1 (enExample) |
| IL (1) | IL236304A0 (enExample) |
| MX (1) | MX2015000541A (enExample) |
| NZ (1) | NZ702967A (enExample) |
| RU (1) | RU2014152445A (enExample) |
| WO (1) | WO2014009241A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813897B2 (en) * | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| NZ702967A (en) * | 2012-07-12 | 2017-07-28 | Ferring Bv | Diclofenac formulations |
| US9855234B2 (en) * | 2014-07-08 | 2018-01-02 | Insys Development Company, Inc. | Diclofenac sublingual spray |
| JP7069042B2 (ja) | 2016-12-28 | 2022-05-17 | 久光製薬株式会社 | 貼付剤 |
| JP7109093B2 (ja) * | 2017-01-31 | 2022-07-29 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 |
| JP7250689B2 (ja) * | 2017-03-07 | 2023-04-03 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 活性化合物のための局所送達系 |
| KR20190101140A (ko) * | 2018-02-22 | 2019-08-30 | 동아제약 주식회사 | 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물 |
| JP7053790B2 (ja) | 2018-02-27 | 2022-04-12 | 久光製薬株式会社 | ジクロフェナク含有乳化ゲル組成物 |
| US20210386858A1 (en) * | 2019-02-19 | 2021-12-16 | Bluepharma - Industria Farmacêutica, S.A. | Mucoadhesive compositions and uses thereof |
| JP6744512B1 (ja) * | 2020-02-12 | 2020-08-19 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
| JP6761553B1 (ja) * | 2020-02-12 | 2020-09-23 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
| BR112022016887A2 (pt) | 2020-02-27 | 2022-10-18 | Ferring Bv | Composições tópicas de diclofenaco e métodos |
| JP2022096994A (ja) * | 2020-12-18 | 2022-06-30 | 小林製薬株式会社 | 外用医薬組成物 |
| US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
| IT202100016751A1 (it) * | 2021-06-25 | 2022-12-25 | Altergon Sa | Formulazione topica di diclofenac ad elevato tasso di assorbimento |
| JP2024538604A (ja) | 2021-10-01 | 2024-10-23 | ニュートリション・アンド・バイオサイエンシーズ・ユーエスエー・ワン，エルエルシー | 局所適用のための親水コロイドブレンド組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| PE20040321A1 (es) | 2002-08-22 | 2004-07-15 | Novartis Consumer Health Sa | Composicion topica que comprende diclofenaco |
| US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0524958D0 (en) | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Transdermal administration of active agents |
| DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
| TW200815045A (en) | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| EP2055298A1 (en) * | 2007-10-30 | 2009-05-06 | Novartis AG | Topical composition |
| US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
| EP2364140A1 (en) | 2008-11-28 | 2011-09-14 | Advance Holdings Limited | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| KR20110127678A (ko) | 2009-03-11 | 2011-11-25 | 코와 가부시키가이샤 | 진통·항염증제 함유 외용제 |
| EP2552418B1 (en) | 2010-03-29 | 2017-08-09 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| NZ702967A (en) * | 2012-07-12 | 2017-07-28 | Ferring Bv | Diclofenac formulations |
-
2013
- 2013-07-04 NZ NZ702967A patent/NZ702967A/en not_active IP Right Cessation
- 2013-07-04 KR KR20157003028A patent/KR20150030752A/ko not_active Withdrawn
- 2013-07-04 CN CN201380036305.1A patent/CN104428003B/zh active Active
- 2013-07-04 BR BR112015000329A patent/BR112015000329A2/pt active Search and Examination
- 2013-07-04 EP EP17190099.6A patent/EP3275466A1/en not_active Withdrawn
- 2013-07-04 AU AU2013289403A patent/AU2013289403B2/en not_active Ceased
- 2013-07-04 US US14/413,922 patent/US9999590B2/en active Active
- 2013-07-04 RU RU2014152445A patent/RU2014152445A/ru not_active Application Discontinuation
- 2013-07-04 MX MX2015000541A patent/MX2015000541A/es unknown
- 2013-07-04 HK HK15105792.2A patent/HK1204973A1/xx unknown
- 2013-07-04 WO PCT/EP2013/064123 patent/WO2014009241A1/en not_active Ceased
- 2013-07-04 JP JP2015520915A patent/JP6259454B2/ja active Active
- 2013-07-04 EP EP13733003.1A patent/EP2872177B1/en not_active Not-in-force
- 2013-07-04 CA CA2878784A patent/CA2878784A1/en not_active Abandoned
-
2014
- 2014-12-16 IL IL236304A patent/IL236304A0/en unknown
-
2017
- 2017-09-22 JP JP2017182383A patent/JP6434104B2/ja active Active
-
2018
- 2018-05-18 US US15/983,911 patent/US10117829B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428003A (zh) | 2015-03-18 |
| CN104428003B (zh) | 2020-03-10 |
| HK1204973A1 (en) | 2015-12-11 |
| JP2018048140A (ja) | 2018-03-29 |
| EP2872177A1 (en) | 2015-05-20 |
| WO2014009241A1 (en) | 2014-01-16 |
| US20150297507A1 (en) | 2015-10-22 |
| JP6259454B2 (ja) | 2018-01-10 |
| CA2878784A1 (en) | 2014-01-16 |
| US10117829B2 (en) | 2018-11-06 |
| EP2872177B1 (en) | 2017-12-20 |
| EP3275466A1 (en) | 2018-01-31 |
| AU2013289403A1 (en) | 2015-01-22 |
| US20180263897A1 (en) | 2018-09-20 |
| MX2015000541A (es) | 2015-05-11 |
| JP6434104B2 (ja) | 2018-12-05 |
| US9999590B2 (en) | 2018-06-19 |
| KR20150030752A (ko) | 2015-03-20 |
| AU2013289403B2 (en) | 2017-05-11 |
| RU2014152445A (ru) | 2016-08-27 |
| JP2015522049A (ja) | 2015-08-03 |
| BR112015000329A2 (pt) | 2017-06-27 |
| IL236304A0 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ702967A (en) | Diclofenac formulations | |
| ZA202007149B (en) | High elasticity hyaluronan compositions and methods of use thereof | |
| MX361858B (es) | Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares. | |
| CA3254865A1 (en) | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders | |
| PH12014502516B1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| PH12014501693A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| HK1209625A1 (en) | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation | |
| MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| MX2016002408A (es) | Metodos para el tratamiento de trastornos oticos pediatricos. | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| MX376783B (es) | Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. | |
| PH12016501159B1 (en) | Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system | |
| MX359686B (es) | Formulaciones de nanoparticulas de polionasol líquidas y en gel. | |
| MX368943B (es) | Formulaciones de tripeptido liofilizado estables en almacenamiento. | |
| MX366118B (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| MX2016003979A (es) | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. | |
| UA80917U (ru) | Гель для местного лечения воспалительных заболеваний опорно-двигательного аппарата на основе продуктов пчеловодства | |
| MD4290B1 (ro) | Cremă antimicrobiană şi antioxidantă pentru tratamentul afecţiunilor cutanate inflamatorii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |